A5056215030- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Multiple Myeloma Research and Treatments
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Chemotherapy-induced cardiotoxicity and mitigation
- Transplantation: Methods and Outcomes
- Organ Transplantation Techniques and Outcomes
- Synthesis of Organic Compounds
- Childhood Cancer Survivors' Quality of Life
- COVID-19 and healthcare impacts
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Fungal Plant Pathogen Control
- Organ and Tissue Transplantation Research
- Mast cells and histamine
Hospital Santa Marcelina
2010-2021
Universidade de São Paulo
2010
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2006-2009
Fundação Pró-Sangue Hemocentro de São Paulo
2003
Tyrosine kinase inhibitors (TKIs) have dramatically changed the survival of chronic myeloid leukemia (CML) patients, and treatment-free remission (TFR) has recently emerged as a new goal CML treatment. The aim this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside clinical trials. A working group experts from LA discussed 22 questions regarding TFR reached consensus region. is indicated patients first phase, with typical BCR-ABL transcripts, under...
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years lower patients with (43% vs. 65%, p 0.07 47% 72%, 0.03, respectively) those (p 0.003 0.03). OS PFS superior subgroup who switched second generation inhibitors (SGIs) after IM failure (OS: 50% 39% 0.01; PFS: 48% 30%...
We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and switched to dasatinib. The phase ( n 2) accelerated CML received dasatinib at starting dose 100 140 mg once daily, respectively. Reappearance hematological toxicity was observed 3 pancreatitis one patient. Treatment given lower were followed. median follow-up 13 months the until achievement complete cytogenetic remission (CCyR) 60 daily (range = 20 120...
This observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia Latin America. A total 92 presented between March and December 2020, 26% whom were severe or critical. The median age at diagnosis was 48 years (22–79 years), 32% 60 older, 61% male. Thirty-nine least one comorbidity (42.3%). Eighty-one recovered (88%), 11 (11.9%) died from COVID-19. There case reinfection. Patients a major molecular response superior overall...
Myeloproliferative neoplasms (MPNs) constitute a group of hematologic clonal diseases that affect one or more myeloid lineages with an abnormal and abundant proliferation.16, 17 The World Health Organization (WHO) currently groups the MPNs into seven categories: Chronic leukemia (CML), chronic neutrophilic (CNL), polycythemia vera (PV), essential thrombocythemia (ET) primary myelofibrosis (PMF), eosinophilic not otherwise specified (NOS) and, unclassifiable myeloproliferative neoplasm...
O imatinibe tem sido confirmado como terapia de primeira linha para a Leucemia Mielóide Crônica (LMC) por apresentar respostas duradouras na maior parte dos pacientes, principalmente nos que se encontram em fase precoce da doença. Entretanto, resistência ou intolerância ao podem ocorrer. A ocorre com muito mais freqüência fases avançadas doença, sendo causa comum o desenvolvimento mutações no sítio BCR-ABL. Em face deste problema, novos inibidores tirosino quinase têm desenvolvidos,...
Coronavirus disease (COVID-19) is an infectious caused by the newly discovered coronavirus Sars-Cov2. In Brazil, first COVID-19 case was diagnosed in February 2020, and since then, number of cases deaths has increased exponentially, reaching 2.610.102 confirmed 91.263 on July 31st. Most people have a mild to moderate respiratory illness, but clinical evolution may be severe older adults patients with comorbidities, such as cancer. There are few reports chronic myeloid leukemia (CML). This...
O mesilato de imatinibe (MI), inibidor seletivo da tirosinoquinase envolvido na patogênese leucemia mielóide crônica (LMC), tem se constituído como terapia farmacológica primeira linha para o tratamento desta doença. A infusão linfócitos do doador (DLI) sido considerada padrão recidiva LMC após transplante medula óssea (TMO) alogênico, apesar estar freqüentemente associado à ocorrência doença enxerto contra hospedeiro e mielossupressão. Por apresentar resultados satisfatórios boa...
To collect data about COVID-19 in CML patients from Brazilian centers and their outcomes. Observational, multicentric, ongoing register study. Hematologists private public reference different regions of Brazil were invited to report cases patients. Those are responsible for the care approximately 3030 Between March 2020 July 2021, 16 institutions contributed this analysis, reported 73 (pts). Eight-five % South Southeast regions, 11% Northeast. The median age was 50 years (22-79), with 33%...